<Table 1>
 <caption text="

   Benefits and challenges in the development of co-formulated drug products
  
">
 </caption>
 <row row="0">
  <cell col="0" row="0" text="Characteristics">
  </cell>
  <cell col="1" row="0" text="Pre-condition">
  </cell>
  <cell col="2" row="0" text="Risk">
  </cell>
 </row>
 <row row="1">
  <cell col="0" row="1" text="Single instead of multiple drug product delivered to the patient, increasing compliance while reducing medical error">
  </cell>
  <cell col="1" row="1" text="Proven synergistic medical benefit and safety from combinational clinical trials">
  </cell>
  <cell col="2" row="1" text="Possible reduction in dosage flexibility
     
     Number of patients that can accept combination therapy could show population and disease variance">
  </cell>
 </row>
 <row row="2">
  <cell col="0" row="2" text="Simplified CMC and logistics">
  </cell>
  <cell col="1" row="2" text="Integration in process development
     
     Stability of each DC does not change significantly in the mixture
     
     Analytics to characterise the degradation of individual drug component in the mixture">
  </cell>
  <cell col="2" row="2" text="More complex control strategy
     
     Availability of analytics
     
     Change in delivery route if co-formulated products have lower concentration tolerance (
     
      e.g.
     
     from SC to IV)
     
     Additional clinical trials are needed to prove the safety of co-formulated products">
  </cell>
 </row>
 <row row="3">
  <cell col="0" row="3" text="New market/product differential strategy">
  </cell>
  <cell col="1" row="3" text="Potential IP extension of existing drugs">
  </cell>
  <cell col="2" row="3" text="New regulation landscape needs to be introduced (potential delay in BLA approval)">
  </cell>
 </row>
 <statements>
  <statement id="0" text="Risk New regulation landscape needs to be introduced (potential delay in BLA approval)Characteristics is New market/product differential strategy." type="entailed">
  </statement>
  <statement id="7" text="A few co-formulated biologic-based products that have been recently approved or are under clinical development suggests an increasing interest in industry to combine biologic therapeutic agents into a single dosage form ( Table 2 )." type="entailed">
  </statement>
 </statements>
</Table 1>